Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $79,866.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,900 shares of Greenwich LifeSciences stock in a transaction on Monday, January 12th. The shares were bought at an average price of $27.54 per share, for a total transaction of $79,866.00. Following the purchase, the chief executive officer owned 5,602,302 shares of the company’s stock, valued at $154,287,397.08. This represents a 0.05% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 13th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $29.83 per share, with a total value of $53,694.00.
• On Wednesday, December 31st, Snehal Patel bought 4,300 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $21.36 per share, for a total transaction of $91,848.00.
• On Tuesday, December 30th, Snehal Patel purchased 2,900 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $21.73 per share, for a total transaction of $63,017.00.
• On Thursday, December 18th, Snehal Patel purchased 4,100 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $12.62 per share, with a total value of $51,742.00.
• On Tuesday, November 25th, Snehal Patel acquired 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel bought 10,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel bought 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Trading Down 8.5%

GLSI opened at $24.88 on Friday. Greenwich LifeSciences, Inc. has a twelve month low of $7.78 and a twelve month high of $32.91. The firm has a market cap of $344.59 million, a price-to-earnings ratio of -17.04 and a beta of 1.47. The company has a fifty day simple moving average of $14.36 and a 200 day simple moving average of $12.05.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.30). On average, analysts forecast that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Greenwich LifeSciences

Large investors have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey acquired a new position in Greenwich LifeSciences in the second quarter worth $25,000. Bank of America Corp DE lifted its position in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Strs Ohio acquired a new position in shares of Greenwich LifeSciences in the 1st quarter valued at about $177,000. Finally, Citadel Advisors LLC grew its position in shares of Greenwich LifeSciences by 52.1% during the 3rd quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after buying an additional 7,174 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on GLSI. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Monday, December 29th. HC Wainwright raised their price target on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 30th. Finally, Wall Street Zen raised shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $47.50.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.